112 results on '"Lindvig, Katrine Prier"'
Search Results
2. Using liver stiffness to predict and monitor the risk of decompensation and mortality in patients with alcohol-related liver disease
3. Screening for Fibrosis Promotes Lifestyle Changes: A Prospective Cohort Study in 4796 Individuals
4. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study
5. Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study
6. Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease
7. Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trial
8. Sphingolipids Are Depleted in Alcohol-Related Liver Fibrosis
9. OS-059 Unveiling Socioeconomic Disparities on Liver Disease: A Comparative Study of ALD, MASLD, and MetALD Patients
10. New nomenclature for fatty liver disease
11. Elastography in Combination with Other Biomarkers: Role of Algorithms
12. Algorithms for Early Detection of Silent Liver Fibrosis in the Primary Care Setting
13. LiverPRO for the Prediction of Significant Liver Fibrosis in Primary Care: Development, Validation, and Prognostic Evaluation of a Novel Score
14. Ketamine as an Anesthetic for Patients with Acute Brain Injury: A Systematic Review
15. Impact of acute alcohol consumption on circulating microbiome in asymptomatic alcohol-related liver disease.
16. Screening for fibrosis promotes life-style changes. A prospective cohort study in 4,796 individuals
17. Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study
18. Binge drinking episode causes acute, specific alterations in systemic and hepatic inflammation‐related markers
19. Terlipressin has acute effects on systemic inflammation markers in patients with cirrhosis and ascites
20. Health-related quality of life in a population at-risk of NAFLD or ArLD
21. Liver stiffness can monitor disease severity and changes predict decompensation in alcohol-related liver disease
22. Clinical course of biopsy-controlled alcohol-related liver disease
23. Cardiovascular events in patients with alcohol-related liver disease and the prognostic value of endotrophin assessed by PRO-C6
24. A cost-comparison of the LiverPRO score with FIB-4, ELF, and FibroScan in 6,032 study participants
25. Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trial
26. Sphingolipids Are Depleted in Alcohol-Related Liver Fibrosis
27. Effect of Calorie-Unrestricted Low-Carbohydrate, High-Fat Diet Versus High-Carbohydrate, Low-Fat Diet on Type 2 Diabetes and Nonalcoholic Fatty Liver Disease:A Randomized Controlled Trial
28. Binge drinking episode causes acute, specific alterations in systemic and hepatic inflammation-related markers
29. SPHINGOLIPIDS ARE DEPLETED IN ALCOHOL-RELATED LIVER FIBROSIS
30. Effect of Calorie-Unrestricted Low-Carbohydrate, High-Fat Diet Versus High-Carbohydrate, Low-Fat Diet on Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
31. Early detection of fatty liver disease in primary care
32. Serum keratin‐18 detects hepatic inflammation and predicts progression in compensated alcohol‐associated liver disease
33. Only one-third of referrals for fatty liver disease are on time: real-world study reveals opportunities to avoid unnecessary and delayed referrals
34. The LiverPRO score, a multivariable model for prediction of significant fibrosis in primary care: derivation, validation and comparison with FIB-4 and ELF-test in 5, 000 study participants
35. A non-calorie restricted low carbohydrate high fat diet improves non-alcoholic fatty liver disease (NAFLD) activity score (NAS) and HbA1c in type 2 diabetes: a six-month randomised controlled trial
36. Does screening for liver fibrosis change alcohol consumption, diet, and exercise? A prospective cohort study on the consequences of screening in 2, 764 individuals
37. Alcohol-induced changes of inflammatory markers in hepatic and systemic venous blood in early alcohol-related and non-alcoholic fatty liver disease
38. Anti-fibrotic effect of rifaximin in early alcohol-related liver disease: a double-blind, randomised, placebo-controlled trial
39. Infections are common in patients with early alcohol-related liver disease and increases the risk of death
40. A derivation and validation study of paired liver and plasma proteomics in 659 individuals reveals circulating biomarkers for alcohol-related liver disease
41. Nonalkoholisk fedtlever-sygdom ved overvægt og metabolisk syndrom
42. Hepatorenal Index by B‐Mode Ratio Versus Imaging and Fatty Liver Index to Diagnose Steatosis in Alcohol‐Related and Nonalcoholic Fatty Liver Disease
43. LiverScreen project: study protocol for screening for liver fibrosis in the general population in European countries
44. THE ACCURACY OF THE ENHANCED LIVER FIBROSIS (ELF) TEST IN A SCREENING SETTING AMONG 3386 PARTICIPANTS
45. Hepatorenal Index by B‐Mode Ratio Versus Imaging and Fatty Liver Index to Diagnose Steatosis in Alcohol‐Related and Nonalcoholic Fatty Liver Disease.
46. Prognostic performance of 7 biomarkers compared to liver biopsy in early alcohol-related liver disease
47. Association of the Liver and Plasma Lipidomes with the Histological Stage of Alcohol-Related Liver Disease
48. Prognostic performance of 7 biomarkers compared to liver biopsy in early alcohol-related liver disease
49. TOP-054 - Health-related quality of life in a population at-risk of NAFLD or ArLD
50. FRI-479 - Liver stiffness can monitor disease severity and changes predict decompensation in alcohol-related liver disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.